AbCellera Biologics Inc. logo

AbCellera Biologics Inc. (ABCL)

Market Closed
11 Jul, 20:00
NASDAQ (NGS) NASDAQ (NGS)
$
4. 01
-0.24
-5.65%
$
1.2B Market Cap
- P/E Ratio
0% Div Yield
5,616,600 Volume
-0.47 Eps
$ 4.25
Previous Close
Day Range
4 4.27
Year Range
1.89 4.33
Want to track ABCL and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 24 days
ABCELLERA BIOLG (ABCL) Upgraded to Buy: Here's Why

ABCELLERA BIOLG (ABCL) Upgraded to Buy: Here's Why

ABCELLERA BIOLG (ABCL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks | 1 month ago
AbCellera Biologics Inc. (ABCL) Q1 2025 Earnings Call Transcript

AbCellera Biologics Inc. (ABCL) Q1 2025 Earnings Call Transcript

AbCellera Biologics Inc. (NASDAQ:ABCL ) Q1 2025 Earnings Conference Call May 8, 2025 5:00 PM ET Company Participants Tryn Stimart - Chief Legal and Compliance Officer Carl Hansen - President and Chief Executive Officer Andrew Booth - Chief Financial Officer Conference Call Participants Jacqueline Kisa - TD Securities Puneet Souda - Leerink Partners LLC Malcolm Hoffman - BMO Capital Markets Srikripa Devarakonda - Truist Securities Operator Good afternoon, and welcome to AbCellera's First Quarter 2025 Business Update and Conference Call. My name is Jasmine, and I will facilitate the audio portion of today's interactive broadcast.

Seekingalpha | 2 months ago
AbCellera Biologics Inc. (ABCL) Reports Q1 Loss, Misses Revenue Estimates

AbCellera Biologics Inc. (ABCL) Reports Q1 Loss, Misses Revenue Estimates

AbCellera Biologics Inc. (ABCL) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to loss of $0.14 per share a year ago.

Zacks | 2 months ago
AbCellera Biologics Inc. (ABCL) Q4 2024 Earnings Call Transcript

AbCellera Biologics Inc. (ABCL) Q4 2024 Earnings Call Transcript

AbCellera Biologics Inc. (NASDAQ:ABCL ) Q4 2024 Earnings Conference Call February 27, 2025 5:00 PM ET Company Participants Tryn Stimart - Chief Legal and Compliance Officer Carl Hansen - Chief Executive Officer Andrew Booth - Chief Financial Officer Conference Call Participants Stephen Willey - Stifel Steve Dechert - KeyBanc Jacqueline Kisa - TD Securities Malcolm Hoffman - BMO Capital Markets Operator Good afternoon and welcome to AbCellera's Full Year 2024 Business Update Conference Call. My name is Tamia [ph] and I will facilitate the audio portion of today's interactive broadcast.

Seekingalpha | 4 months ago
AbCellera Biologics Inc. (ABCL) Reports Q4 Loss, Misses Revenue Estimates

AbCellera Biologics Inc. (ABCL) Reports Q4 Loss, Misses Revenue Estimates

AbCellera Biologics Inc. (ABCL) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to loss of $0.17 per share a year ago.

Zacks | 4 months ago
AbCellera Biologics: Still A Concept Stock

AbCellera Biologics: Still A Concept Stock

Today, we revisit a somewhat unique developmental company called AbCellera Biologics Inc. The company is moving towards focusing more on its wholly owned candidates off its platform rather than partnerships. The company has myriad very early-stage assets in development, and ABCL stock trades near the net cash on its balance sheet.

Seekingalpha | 6 months ago
AbCellera Biologics Inc. (ABCL) Q3 2024 Earnings Call Transcript

AbCellera Biologics Inc. (ABCL) Q3 2024 Earnings Call Transcript

AbCellera Biologics Inc. (NASDAQ:ABCL ) Q3 2024 Earnings Conference Call November 4, 2024 5:00 PM ET Company Participants Tryn Stimart - Chief Legal and Compliance Officer Carl Hansen - Chief Executive Officer Andrew Booth - Chief Financial Officer Conference Call Participants Allison Bratzel - Piper Sandler Andrea Tan - Goldman Sachs Srikripa Devarakonda - Truist Securities Evan Seigerman - BMO David Martin - Bloom Burton Brendan Smith - TD Securities Operator Good afternoon, and welcome to AbCellera's Q3 2024 Business Update Conference Call. My name is Tamiya, and I will facilitate the audio portion of today's interactive broadcast.

Seekingalpha | 8 months ago
AbCellera Biologics Inc. (ABCL) Reports Q3 Loss, Misses Revenue Estimates

AbCellera Biologics Inc. (ABCL) Reports Q3 Loss, Misses Revenue Estimates

AbCellera Biologics Inc. (ABCL) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to loss of $0.10 per share a year ago.

Zacks | 8 months ago
AbCellera: A Platform To Pipeline Transition

AbCellera: A Platform To Pipeline Transition

AbCellera is shifting its focus from a platform biotech company to its internal drug pipeline. The company's lead asset, ABCL575, comes with a variety of risks, but in our opinion, has a value of a little over $1B and is derisked based on comparable therapeutics. AbCellera is on track to submit ABCL575 for clinical trials in Q22025, helping the market reset its valuation on the company closer to the value of the lead asset.

Seekingalpha | 9 months ago
AbCellera: A Waiting Game With High Uncertainty

AbCellera: A Waiting Game With High Uncertainty

AbCellera's Q2 2024 revenue declined by 27% year-over-year to $7.3 million. The company's net loss widened to $36.9 million due to increased R&D expenses. AbCellera's cash and marketable securities totaled $697.6 million, with total liquidity exceeding $900 million.

Seekingalpha | 10 months ago
AbCellera Biologics Inc. (ABCL) Reports Q2 Loss, Misses Revenue Estimates

AbCellera Biologics Inc. (ABCL) Reports Q2 Loss, Misses Revenue Estimates

AbCellera Biologics Inc. (ABCL) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to loss of $0.11 per share a year ago.

Zacks | 11 months ago
5 Penny Stocks With 250% Upside in 1 Year According to Wall Street

5 Penny Stocks With 250% Upside in 1 Year According to Wall Street

Penny stocks represent an interesting investment opportunity.

247wallst | 11 months ago
Loading...
Load More